Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0AC0A
|
|||
Former ID |
DIB000605
|
|||
Drug Name |
SB-612111
|
|||
Synonyms |
N/OFQ receptor antagonist (inflammatory disease), SRI International
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Inflammation [ICD-11: 1A00-CA43.1] | Investigative | [1] | |
Company |
SRI International
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H29Cl2NO
|
|||
Canonical SMILES |
CC1=C2CCC(CC(C2=CC=C1)O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl
|
|||
InChI |
1S/C24H29Cl2NO/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26/h2-7,17-18,23,28H,8-15H2,1H3/t17-,23-/m0/s1
|
|||
InChIKey |
OHRDCQFCAWLDBP-SBUREZEXSA-N
|
|||
CAS Number |
CAS 371980-98-2
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Nociceptin receptor (OPRL1) | Target Info | Antagonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1693). | |||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.